Abstract
Aldose reductase (AR) is an enzyme that catalyzes the rate limiting step of the polyol pathway of glucose metabolism. Besides reducing glucose to sorbitol, it reduces a number of lipid peroxidation derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, it also has a pivotal role in inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and ovarian cancer. Furthermore, an excess of AR is found in different human cancers, such as liver, colon, breast, and cervical cancer. AR inhibitors have undergone up to phase-III clinical trials for diabetic complications. They are also reported as safe anti-inflammatory drugs. Therefore, future use of AR inhibitors in down-regulating major multi-diseases and inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns worldwide.
Keywords: Aldose reductase inhibitors, diabetic neuropathy, inflammatory pathologies, polyol pathway.
Current Enzyme Inhibition
Title:Aldose Reductase: A Multi-disease Target
Volume: 10 Issue: 1
Author(s): Jaiprakash N. Sangshetti, Rashmi S. Chouthe, Nikhil S. Sakle, Indrajeet Gonjari and Devanand B. Shinde
Affiliation:
Keywords: Aldose reductase inhibitors, diabetic neuropathy, inflammatory pathologies, polyol pathway.
Abstract: Aldose reductase (AR) is an enzyme that catalyzes the rate limiting step of the polyol pathway of glucose metabolism. Besides reducing glucose to sorbitol, it reduces a number of lipid peroxidation derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, it also has a pivotal role in inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and ovarian cancer. Furthermore, an excess of AR is found in different human cancers, such as liver, colon, breast, and cervical cancer. AR inhibitors have undergone up to phase-III clinical trials for diabetic complications. They are also reported as safe anti-inflammatory drugs. Therefore, future use of AR inhibitors in down-regulating major multi-diseases and inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns worldwide.
Export Options
About this article
Cite this article as:
Sangshetti N. Jaiprakash, Chouthe S. Rashmi, Sakle S. Nikhil, Gonjari Indrajeet and Shinde B. Devanand, Aldose Reductase: A Multi-disease Target, Current Enzyme Inhibition 2014; 10 (1) . https://dx.doi.org/10.2174/15734080113096660007
DOI https://dx.doi.org/10.2174/15734080113096660007 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Transplacental Antioxidants Inhibit Lung Tumors in Mice Exposed to Cigarette Smoke After Birth: A Novel Preventative Strategy?
Current Cancer Drug Targets Role of Adiponectin in Cervical Cancer
Current Drug Metabolism Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery The Endocannabinoid System in the Cancer Therapy: An Overview
Current Medicinal Chemistry Trigonelline: A Plant Alkaloid with Therapeutic Potential for Diabetes and Central Nervous System Disease
Current Medicinal Chemistry Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Metformin Protects the Brain Against the Oxidative Imbalance Promoted by Type 2 Diabetes
Medicinal Chemistry Recapitulation of Cancer Nanotherapeutics
Current Nanomedicine Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges
Current Medicinal Chemistry Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Oncogene Suppression by Small Interfering RNAs
Current Pharmaceutical Biotechnology SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets